Veracyte Inc (VCYT) 4.98 $VCYT Veracyte to Host

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Veracyte Inc (VCYT) 4.98 $VCYT

Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2016 Financial Results on Wednesday, August 3, 2016
PR Newswire - Tue Jul 12, 7:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its second quarter 2016 financial results after close of market on Wednesday, August 3, 2016. Following the announcement, Veracyte's management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company's financial results and business progress.
VCYT: 4.98 (+0.03)

Veracyte Releases Statement on CMS's Final PAMA Rule
PR Newswire - Fri Jun 17, 5:51PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, issued the following statement in response to the Centers for Medicare and Medicaid Services' (CMS) release today of its final rule outlining how the agency will establish Medicare reimbursement rates for advanced genomic tests such as Veracyte's Afirma® Gene Expression Classifier (GEC) under the Protecting Access to Medicare Act (PAMA), beginning January 1, 2018.
VCYT: 4.98 (+0.03)

Veracyte Statement on CMS's Preliminary Gapfill Rate for the Afirma® Gene Expression Classifier
PR Newswire - Fri Jun 10, 8:45PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today issued the statement below on the Centers for Medicare and Medicaid Services' (CMS) preliminary "gapfill" Medicare reimbursement rate for Veracyte's Afirma Gene Expression Classifier (GEC), which the agency released this afternoon.
VCYT: 4.98 (+0.03)

Veracyte to Present at the William Blair & Company 36th Annual Growth Stock Conference
PR Newswire - Wed Jun 01, 7:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that Chris Hall, chief operating officer, will present at the William Blair & Company 36th Annual Growth Stock Conference on Wednesday, June 15th, 2016 at 2:40 p.m. CT in Chicago, IL.
VCYT: 4.98 (+0.03)

Veracyte Announces New Data that Advance Understanding of the Role of Gene Alterations In Thyroid Cancer Diagnosis
PR Newswire - Fri May 27, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced findings from two studies demonstrating the challenge of using large gene-mutation panels to help physicians determine next steps for patients whose thyroid nodules are not clearly benign or malignant following routine cytopathology evaluation. Company researchers also unveiled a new study designed to identify RNA-based gene alteration and other data that may be useful in guiding physician decision-making for thyroid nodule patients. The studies are being presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific & Clinical Congress, taking place May 25-29, 2016, in Orlando, Fla.
VCYT: 4.98 (+0.03)

Veracyte Announces Data from Multiple Studies Advancing Scientific Understanding of Thyroid Cancer to Be Presented at AACE Congress
PR Newswire - Mon May 23, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that company scientists and external researchers will present new data advancing the science around the role of gene alterations and transcriptions in thyroid cancer diagnosis at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific & Clinical Congress taking place May 25-29, 2016, in Orlando, Fla.
VCYT: 4.98 (+0.03)

New Data Demonstrating Ability of Veracyte's Genomic Test to Improve Idiopathic Pulmonary Fibrosis Diagnosis Presented at ATS 2016
PR Newswire - Tue May 17, 4:30PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced findings from a new study demonstrating the potential for the company's in-development Envisia classifier to help distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILD) without the need for invasive and potentially risky surgery. Additional data from three other studies suggest the potential for the test to address several challenges that currently hinder accurate and timely diagnosis of the disease. The findings were presented at the American Thoracic Society (ATS) 2016 International Conference taking place May 13-18 in San Francisco.
VCYT: 4.98 (+0.03)

Veracyte reports 1Q loss
Automated Insights - Thu May 05, 4:15PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Thursday reported a loss of $10.1 million in its first quarter.
VCYT: 4.98 (+0.03)

Veracyte Announces First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 3:05PM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced financial results for the first quarter ended March 31, 2016 and provided an update on recent business progress. For the first quarter of 2016, revenue was $13.6 million, an increase of 21%, compared to $11.2 million for the first quarter of 2015. Afirma Gene Expression Classifier (GEC) test volume grew to 5,352 tests, an increase of 33%, compared to the same period in 2015.
VCYT: 4.98 (+0.03)

/C O R R E C T I O N -- Veracyte/
PR Newswire - Tue Apr 19, 11:01AM CDT
In the news release, Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results on Thursday, May 5, 2016, issued 19-Apr-2016 by Veracyte over PR Newswire, we are advised by the company that the first paragraph, first sentence, should read "Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its first quarter 2016 financial results after close of market on Thursday, May 5, 2016" rather than "Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its fourth quarter and full-year 2015 financial results after close of market on Thursday, May 5, 2016" as originally issued inadvertently. The complete, corrected release follows:
VCYT: 4.98 (+0.03)

Clinical Utility of Veracyte's Afirma® Gene Expression Classifier Demonstrated in Multiple Studies Presented at ENDO 2016
PR Newswire - Sat Apr 02, 12:15PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced findings from two new studies demonstrating the clinical utility of the Afirma Gene Expression Classifier (GEC). The genomic test is used to rule out cancer in thyroid nodules deemed indeterminate (not clearly benign or malignant) following traditional cytopathology evaluation so that these patients can potentially avoid an unnecessary surgery. The findings were presented today at ENDO 2016, the annual meeting of the Endocrine Society, being held April 1-4 in Boston.
VCYT: 4.98 (+0.03)

Multiple Studies Showcasing Clinical Utility of Veracyte's Afirma® Gene Expression Classifier to Be Presented at ENDO 2016
PR Newswire - Tue Mar 29, 3:05PM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that company and external researchers will deliver poster presentations demonstrating the clinical utility of the Afirma Gene Expression Classifier (GEC) in thyroid cancer diagnosis, as well as advancing the genomic science around thyroid malignancy, at ENDO 2016, the annual conference of The Endocrine Society, being held April 1-4 in Boston.
VCYT: 4.98 (+0.03)

Veracyte Secures Up to $45 Million in Financing from Visium Healthcare Partners
PR Newswire - Mon Mar 28, 7:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, and Visium Healthcare Partners, LP, a healthcare investment firm, today announced that they have entered into an agreement that provides up to $45 million of financing, comprising a term loan agreement and securities purchase option. On a pro forma basis, net proceeds from the new loan facility and the cash and cash equivalents as of December 31, 2015 provide Veracyte with approximately $73 million to fund the continued growth of the company's core business.
VCYT: 4.98 (+0.03)

New Study Supports Use of Veracyte's Medullary Thyroid Cancer Classifier as Part of Its Comprehensive Afirma Solution
PR Newswire - Tue Mar 22, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced that data from a large, prospective clinical study demonstrate the accuracy of the company's medullary thyroid cancer (MTC) classifier and its potential - when used with the Afirma® Gene Expression Classifier (GEC) - to provide a more clinically useful way to diagnose this aggressive cancer preoperatively, compared to traditional methods. The findings are published online in the journal Thyroid.
VCYT: 4.98 (+0.03)

New Data Show That Veracyte's Afirma® Gene Expression Classifier Reduces Unnecessary Thyroid Surgeries and Costs During Long-Term Follow-Up
PR Newswire - Wed Mar 16, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced publication of data demonstrating that the Afirma Gene Expression Classifier (GEC) reduces unnecessary surgeries in thyroid cancer diagnosis during long-term clinical follow-up. The study is the first to use a national healthcare claims database to determine the real-world impact of the genomic test on patient care and to quantify the costs associated with thyroid surgery. The findings appear online in the journal Current Medical Research & Opinion.
VCYT: 4.98 (+0.03)

Veracyte Announces Fourth Quarter and Full-Year 2015 Financial Results, Provides 2016 Financial Outlook
PR Newswire - Thu Mar 10, 3:05PM CST
Veracyte, Inc. (NASDAQ: VCYT) today announced financial results and business progress for the quarter and full year ended December 31, 2015, and provided financial guidance for 2016.
VCYT: 4.98 (+0.03)

Veracyte Receives Regulatory Authorization to Offer Percepta(TM) Bronchial Genomic Classifier for Patients in New York State
PR Newswire - Thu Jan 28, 6:30AM CST
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that it has received regulatory authorization from the New York State Department of Health to offer the Percepta(TM) Bronchial Genomic Classifier for patients in the state. The genomic test, commercially introduced in April 2015, is used to help patients avoid unnecessary invasive, risky and costly procedures to assess potentially cancerous lung nodules that were initially found on CT scans.
VCYT: 4.98 (+0.03)

Veracyte to Participate in Two Upcoming Investor Conferences
PR Newswire - Wed Jan 27, 7:00AM CST
Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10th 2016 at 11:05 a.m. ET in New York, NY.
VCYT: 4.98 (+0.03)

Air Methods (AIRM) Completes Tri-State Care Flight Buyout
Zacks Equity Research - Zacks Investment Research - Wed Jan 20, 12:10PM CST
Air Methods (AIRM) recently completed the previously announced acquisition of Tri-State Care Flight for $22.5 million.
ISRG: 693.87 (-1.89), VCYT: 4.98 (+0.03), AIRM: 32.70 (-0.59), EXAC: 27.20 (+0.17)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 205

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 210

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny

Updated Category News Views 135

Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...

Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 58

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 181

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 22

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 156

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 178

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading

Top 5 Most Recently Viewed Articles

Streamlined Shipping Solutions for UK Businesses by Wix.com

Updated Category News Views 279

Enhancing Shipping for UK Businesses with Wix.com Wix.com Ltd. (NASDAQ: WIX) has taken a significant step forward in supporting UK businesses by integrating Royal Mail within its innovative Wix Shipping platform. This breakthrough means that merchants can now easily transition from traditional, manual shipping processes to a fully automated system, streamlining their...

Continue Reading
FullFlex.Agency Innovation: AI Solutions for Business Growth

Updated Category News Views 147

FullFlex.Agency Unleashes Innovative Marketing Solutions FullFlex.Agency is celebrating its continued success as it enters the fourth quarter of its second year. This dynamic organization, known for its robust AI-powered marketing solutions and transparent pricing structures, emphasizes its commitment to helping businesses thrive across various sectors. Expansion of...

Continue Reading
NexBank Achieves Recognition as Leading Mortgage Lender

Updated Category News Views 207

NexBank: A Consistent Leader in Mortgage Lending NexBank has once again made headlines by being recognized as one of the top mortgage lenders in the nation for the fourth consecutive year. This achievement underscores the bank's ongoing commitment to excellence in the mortgage industry. The latest rankings show that NexBank secured the 12th position for Correspondent...

Continue Reading
First Mining Gold Corp. Strengthens Position with First Majestic

Updated Category News Views 173

Key Agreement Enhancements Between First Mining Gold and First Majestic First Mining Gold Corp. (TSX: FF) has announced an important agreement with First Majestic Silver Corp. that is expected to positively impact its financial position and operational strategy. This mutually beneficial arrangement revises the parameters of the existing silver purchase agreement,...

Continue Reading
Expert Weighs In: College Apps Need Strategy, Not Count

Updated Category News Views 38

A Lesson for College-Bound Families When the question comes up about college applications, you expect to hear numbers thrown around like eight, twelve, or even twenty. But the idea that there's some magic number to crack the admissions code? It just doesn't hold water. Instead, it's all about the risk baked into your list of schools. That's where HelloCollege's recent...

Continue Reading